+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myocardial Infarction - Pipeline Review, H2 2019

  • ID: 4861713
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 332 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Actinogen Medical Ltd
  • Bharat Biotech Ltd
  • DepYmed Inc
  • Innolife Co Ltd
  • Mirae Cell Bio Co Ltd
  • Qurgen Inc
  • MORE
Myocardial Infarction - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H2 2019, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 15, 11, 1, 49, 9 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 18 and 4 molecules, respectively.

Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actinogen Medical Ltd
  • Bharat Biotech Ltd
  • DepYmed Inc
  • Innolife Co Ltd
  • Mirae Cell Bio Co Ltd
  • Qurgen Inc
  • MORE
Introduction
Myocardial Infarction - Overview
Myocardial Infarction - Therapeutics Development
Myocardial Infarction - Therapeutics Assessment
Myocardial Infarction - Companies Involved in Therapeutics Development
Myocardial Infarction - Drug Profiles
Myocardial Infarction - Dormant Projects
Myocardial Infarction - Discontinued Products
Myocardial Infarction - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Myocardial Infarction, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Myocardial Infarction - Pipeline by Actinogen Medical Ltd, H2 2019
Myocardial Infarction - Pipeline by Angion Biomedica Corp, H2 2019
Myocardial Infarction - Pipeline by Ankasa Regenerative Therapeutics Inc, H2 2019
Myocardial Infarction - Pipeline by Aposcience AG, H2 2019
Myocardial Infarction - Pipeline by Applied Therapeutics Inc, H2 2019
Myocardial Infarction - Pipeline by Aprogen Inc, H2 2019
Myocardial Infarction - Pipeline by APT Therapeutics Inc, H2 2019
Myocardial Infarction - Pipeline by AstraZeneca Plc, H2 2019
Myocardial Infarction - Pipeline by Athera Biotechnologies AB, H2 2019
Myocardial Infarction - Pipeline by Athersys Inc, H2 2019
Myocardial Infarction - Pipeline by Axolo Pharma Inc, H2 2019
Myocardial Infarction - Pipeline by Beijing Northland Biotech Co Ltd, H2 2019
Myocardial Infarction - Pipeline by Bharat Biotech Ltd, H2 2019
Myocardial Infarction - Pipeline by BioCardia Inc, H2 2019
Myocardial Infarction - Pipeline by Cadila Healthcare Ltd, H2 2019
Myocardial Infarction - Pipeline by CardioCreate Inc, H2 2019
Myocardial Infarction - Pipeline by Cardiol Therapeutics Inc, H2 2019
Myocardial Infarction - Pipeline by Cardior Pharmaceuticals GmbH, H2 2019
Myocardial Infarction - Pipeline by CeleCor Therapeutics Inc, H2 2019
Myocardial Infarction - Pipeline by Celixir Ltd, H2 2019
Myocardial Infarction - Pipeline by CellProthera SAS, H2 2019
Myocardial Infarction - Pipeline by CFM Pharma Holding BV, H2 2019
Myocardial Infarction - Pipeline by Cynata Therapeutics Ltd, H2 2019
Myocardial Infarction - Pipeline by DepYmed Inc, H2 2019
Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc, H2 2019
Myocardial Infarction - Pipeline by Domainex Ltd, H2 2019
Myocardial Infarction - Pipeline by Ever Supreme Bio Technology Co Ltd, H2 2019
Myocardial Infarction - Pipeline by Evotec SE, H2 2019
Myocardial Infarction - Pipeline by EyeGene Inc, H2 2019
Myocardial Infarction - Pipeline by Faraday Pharmaceuticals Inc, H2 2019
Myocardial Infarction - Pipeline by General Regeneratives Shanghai Ltd, H2 2019
Myocardial Infarction - Pipeline by Generium, H2 2019
Myocardial Infarction - Pipeline by GNT Pharma Co Ltd, H2 2019
Myocardial Infarction - Pipeline by Hemostemix Inc, H2 2019
Myocardial Infarction - Pipeline by Honya Medical Inc, H2 2019
Myocardial Infarction - Pipeline by HUYA Bioscience International LLC, H2 2019
Myocardial Infarction - Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
Myocardial Infarction - Pipeline by iHeart Japan Corp, H2 2019
Myocardial Infarction - Pipeline by InCarda Therapeutics Inc, H2 2019
Myocardial Infarction - Pipeline by Innolife Co Ltd, H2 2019
Myocardial Infarction - Pipeline by Inotrem SA, H2 2019
Myocardial Infarction - Pipeline by IPS Heart Inc, H2 2019
Myocardial Infarction - Pipeline by K-Stemcell Co Ltd, H2 2019
Myocardial Infarction - Pipeline by Kine Sciences, H2 2019
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2019
Myocardial Infarction - Pipeline by LTT Bio-Pharma Co Ltd, H2 2019
Myocardial Infarction - Pipeline by MandalMed Inc, H2 2019
Myocardial Infarction - Pipeline by Mesoblast Ltd, H2 2019
Myocardial Infarction - Pipeline by MIFCOR Inc, H2 2019
Myocardial Infarction - Pipeline by MimeTech Srl, H2 2019
Myocardial Infarction - Pipeline by Mirae Cell Bio Co Ltd, H2 2019
Myocardial Infarction - Pipeline by New World Laboratories Inc, H2 2019
Myocardial Infarction - Pipeline by Novartis AG, H2 2019
Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H2 2019
Myocardial Infarction - Pipeline by OMEICOS Therapeutics GmbH, H2 2019
Myocardial Infarction - Pipeline by OP2 Drugs SAS, H2 2019
Myocardial Infarction - Pipeline by Opsona Therapeutics Ltd, H2 2019
Myocardial Infarction - Pipeline by OtiTopic LLC, H2 2019
Myocardial Infarction - Pipeline by Pharmahungary Group, H2 2019
Myocardial Infarction - Pipeline by Primary Peptides Inc, H2 2019
Myocardial Infarction - Pipeline by Quark Pharmaceuticals Inc, H2 2019
Myocardial Infarction - Pipeline by Qurgen Inc, H2 2019
Myocardial Infarction - Pipeline by Reata Pharmaceuticals Inc, H2 2019
Myocardial Infarction - Pipeline by Recardio GmbH, H2 2019

List of Figures
Number of Products under Development for Myocardial Infarction, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Actinogen Medical Ltd
  • Angion Biomedica Corp
  • Ankasa Regenerative Therapeutics Inc
  • Aposcience AG
  • Applied Therapeutics Inc
  • Aprogen Inc
  • APT Therapeutics Inc
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • Athersys Inc
  • Axolo Pharma Inc
  • Beijing Northland Biotech Co Ltd
  • Bharat Biotech Ltd
  • BioCardia Inc
  • Cadila Healthcare Ltd
  • CardioCreate Inc
  • Cardiol Therapeutics Inc
  • Cardior Pharmaceuticals GmbH
  • CeleCor Therapeutics Inc
  • Celixir Ltd
  • CellProthera SAS
  • CFM Pharma Holding BV
  • Cynata Therapeutics Ltd
  • DepYmed Inc
  • Diffusion Pharmaceuticals Inc
  • Domainex Ltd
  • Ever Supreme Bio Technology Co Ltd
  • Evotec SE
  • EyeGene Inc
  • Faraday Pharmaceuticals Inc
  • General Regeneratives Shanghai Ltd
  • Generium
  • GNT Pharma Co Ltd
  • Hemostemix Inc
  • Honya Medical Inc
  • HUYA Bioscience International LLC
  • Idorsia Pharmaceutical Ltd
  • iHeart Japan Corp
  • InCarda Therapeutics Inc
  • Innolife Co Ltd
  • Inotrem SA
  • IPS Heart Inc
  • K-Stemcell Co Ltd
  • Kine Sciences
  • Lee's Pharmaceutical Holdings Ltd
  • LTT Bio-Pharma Co Ltd
  • MandalMed Inc
  • Mesoblast Ltd
  • MIFCOR Inc
  • MimeTech Srl
  • Mirae Cell Bio Co Ltd
  • New World Laboratories Inc
  • Novartis AG
  • NuvOx Pharma LLC
  • OMEICOS Therapeutics GmbH
  • OP2 Drugs SAS
  • Opsona Therapeutics Ltd
  • OtiTopic LLC
  • Pharmahungary Group
  • Primary Peptides Inc
  • Quark Pharmaceuticals Inc
  • Qurgen Inc
  • Reata Pharmaceuticals Inc
  • Recardio GmbH
  • RegeneRx Biopharmaceuticals Inc
  • Reliance Life Sciences Pvt Ltd
  • ResoTher Pharma ApS
  • Rubicon Biotechnology Inc
  • Sentan Pharma Inc
  • Serpin Pharma LLC
  • Silver Creek Pharmaceuticals Inc
  • SmartPharm Therapeutics Inc
  • Sorrento Therapeutics Inc
  • T&R Biofab Co Ltd
  • TaiGen Biotechnology Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Techfields Pharma Co Ltd
  • Thrombolytic Science International LLC
  • Translational Sciences Inc
  • Vaxil Bio Therapeutics Ltd
  • XBiotech Inc
  • Xcelthera INC
  • Yichang Humanwell Pharmaceutical Co Ltd
  • Yuyu Pharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll